Masato Ozaka

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 8

Top Topics

Genome Wide Association

Squamous Cell Carcinoma

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Top Venues

Cancer chemotherapy and pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Takafumi Mie, Takashi Sasaki, Tsuyoshi Takeda, Takeshi Okamoto, Tsuyoshi Hamada, Takahiro Ishitsuka, Manabu Yamada, Hiroki Nakagawa, Takaaki Furukawa, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka, Naoki Sasahira
Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer. Cancers 15 (2) (2023)
Takeshi Okamoto, Tsuyoshi Takeda, Takafumi Mie, Tatsuki Hirai, Takahiro Ishitsuka, Manabu Yamada, Hiroki Nakagawa, Takaaki Furukawa, Akiyoshi Kasuga, Takashi Sasaki, Masato Ozaka, Naoki Sasahira
Splenic Hilar Involvement and Sinistral Portal Hypertension in Unresectable Pancreatic Tail Cancer. Cancers 15 (24) (2023)
Takafumi Mie, Takashi Sasaki, Tsuyoshi Takeda, Takeshi Okamoto, Tsuyoshi Hamada, Takahiro Ishitsuka, Manabu Yamada, Hiroki Nakagawa, Takaaki Furukawa, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka, Naoki Sasahira
Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer. Cancers 15 (2) (2023)
Takafumi Mie, Takashi Sasaki, Tsuyoshi Takeda, Takeshi Okamoto, Tsuyoshi Hamada, Takahiro Ishitsuka, Manabu Yamada, Hiroki Nakagawa, Takaaki Furukawa, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka, Naoki Sasahira
Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer. Cancers 15 (2) (2023)
Takafumi Mie, Takashi Sasaki, Tsuyoshi Takeda, Takeshi Okamoto, Tsuyoshi Hamada, Takahiro Ishitsuka, Manabu Yamada, Hiroki Nakagawa, Takaaki Furukawa, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka, Naoki Sasahira
Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer. Cancers 15 (2) (2023)
Takeshi Okamoto, Tsuyoshi Takeda, Takafumi Mie, Tatsuki Hirai, Takahiro Ishitsuka, Manabu Yamada, Hiroki Nakagawa, Takaaki Furukawa, Akiyoshi Kasuga, Takashi Sasaki, Masato Ozaka, Naoki Sasahira
Splenic Hilar Involvement and Sinistral Portal Hypertension in Unresectable Pancreatic Tail Cancer. Cancers 15 (24) (2023)
Masato Ozaka, Hiroshi Ishii, Tosiya Sato, Makoto Ueno, Masafumi Ikeda, Kazuhiro Uesugi, Naohiro Sata, Kouichirou Miyashita, Nobumasa Mizuno, Kunihiro Tsuji, Takuji Okusaka, Junji Furuse
A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. Cancer chemotherapy and pharmacology 81 (6) (2018)
Masahiro Nakatochi, Yingsong Lin, Hidemi Ito, Kazuo Hara, Fumie Kinoshita, Yumiko Kobayashi, Hiroshi Ishii, Masato Ozaka, Takashi Sasaki, Naoki Sasahira, Manabu Morimoto, Satoshi Kobayashi, Makoto Ueno, Shinichi Ohkawa, Naoto Egawa, Sawako Kuruma, Mitsuru Mori, Haruhisa Nakao, Chaochen Wang, Takeshi Nishiyama, Takahisa Kawaguchi, Meiko Takahashi, Fumihiko Matsuda, Shogo Kikuchi, Keitaro Matsuo
Prediction model for pancreatic cancer risk in the general Japanese population. PloS one 13 (9) (2018)